Medicine
Rituxan Hycela 2000 units/120 mg per mL injection
Rituxan Hycela 2000 units/120 mg per mL injection is a prescription medicine containing Hyaluronidase (human recombinant) and Rituximab for subcutaneous use, marketed by Genentech, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Store RITUXAN HYCELA vials in the refrigerator at 2°C to 8°C (36°F to 46°F) in…
Key facts
- Active ingredient (INN)
- Hyaluronidase (human recombinant) and Rituximab
- Brand
- Rituxan Hycela
- Strength
- 2000 units/120 mg per mL
- Dosage form
- Injection
- Route
- Subcutaneous
- Packs
- 1 vial
- Marketing authorisation holder
- Genentech
- Manufacturer
- Genentech
- Origin register
- US FDA, United States
- Storage
- Store RITUXAN HYCELA vials in the refrigerator at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light. Do not freeze.
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- HS code (indicative)
- 3002.15Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 22 June 2017
- Identifiers
- RxCUI 1927885, 1927890, 1927893 +1DailyMed set ID 3e5b7e82-f018-4eaf-ae78-d6145a906b20NDC 50242-108, 50242-109Application BLA761064
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 22 June 2017 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Hyaluronidase (human recombinant) and Rituximab is a fixed-dose combination of a CD20-directed cytolytic antibody and an endoglycosidase indicated for the treatment of adult patients with follicular Lymphoma (FL), among other approved uses. MedsAcross supplies Hyaluronidase (human recombinant) and Rituximab for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Hyaluronidase (human recombinant) and RituximabFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Rituxan Hycela prescribing information (Genentech) · U.S. National Library of Medicine, DailyMed
Need Rituxan Hycela 2000 units/120 mg per mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.